2020 ASCO Virtual Direct™ Highlights

 

Breast
06:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mTNBC: Does Atezolizumab + Chemo Combo Improve PFS?

FEATURING Elyse Lower
  • 217 views
  • October 13, 2020
  • 2
08:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on MBC: Is Olaparib Beneficial for Disease With sBRCA1/2 or gPALB2 Mutations?

FEATURING Elyse Lower
  • 221 views
  • October 13, 2020
06:52

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Is Tucatinib + Trastuzumab/Capecitabine Combination an Active Regimen for Intracranial/Extracranial Disease?

FEATURING Elyse Lower
  • 100 views
  • October 13, 2020
06:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on PIK3CA Mutated HR+ Advanced BC: Is the Addition of Alpelisib + Fulvestrant Effective Post-CDKi and AI?

FEATURING Elyse Lower
  • 236 views
  • October 13, 2020
  • 2
06:32

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ MBC: Is Fulvestrant + CDKi Associated With Improved PFS and OS?

FEATURING Elyse Lower
  • 359 views
  • October 13, 2020
  • 3
08:54

2020 ASCO Virtual Direct™ Highlights

2020 ASCO HIghlights on Prostate Cancer: Does PSMA-Targeted Imaging with 18F-DCFPyL-PET/CT Impact Clinical Management of Biochemically Recurrent Prostate Cancer?

FEATURING Vivek Narayan
  • 188 views
  • August 6, 2020
08:20

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on High-Risk HER2+ Early BC: Adjuvant T-DM1 + Pertuzumab vs. SoC - Did KAITLIN Study Demonstrate Improvement in IDFS?

FEATURING Kevin Kalinsky
  • 128 views
  • August 6, 2020
  • 1
07:57

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ BC: Should We Add Anthracyclines to Neoadjuvant Chemo in the Presence of Dual HER2-Blockade?

FEATURING Kevin Kalinsky
  • 354 views
  • August 6, 2020
  • 3
12:32

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ BC: Does Neoadjuvant Endocrine Combination Therapy Have a Greater Effect on ESDR vs. Monotherapy in Early Stage BC? Should We Consider MammaPrint a Guidance Tool for Precision Adjuvant Therapy?

FEATURING Kevin Kalinsky
  • 523 views
  • August 6, 2020
  • 4
14:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on Curative HER2+ BC: Preoperative Systemic Therapy, Neoadjuvant Trastuzumab/Pertuzumab, Anthracycline vs. Non-Anthracycline-Based Regimens, Duration Trastuzumab

FEATURING Kevin Kalinsky
  • 188 views
  • August 26, 2020
  • 2
12:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recent FDA Approvals for Adjuvant HER2+ EBC: Neratinib, Pertuzumab & T-DM-1 - How Much Benefit Can Be Expected?

FEATURING Kevin Kalinsky
  • 236 views
  • August 26, 2020
  • 1
12:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ MBC: Incorporating New HER2 Targeted Agents - Neratinib, Pertuzumab & T-DM-1

FEATURING Kevin Kalinsky
  • 219 views
  • August 26, 2020
  • 2